Plain-English translation of NCT04380038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing dupilumab, a medication that works differently than standard asthma treatments, to see if it can prevent asthma from getting worse when you catch a cold virus (especially rhinovirus). About half of the 60 participants will receive the medication, and half will receive a placebo (a fake injection that looks identical). Researchers want to understand how this treatment protects your airways and immune system during a viral infection.
Colds caused by rhinovirus trigger asthma flare-ups in up to 80% of children and teenagers, and scientists don't fully understand why. This medication is already approved for asthma, but this study is investigating exactly how it might prevent those viral-triggered flare-ups — knowledge that could help better protect asthma patients in the future.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for screening and baseline tests, then receive either the medication or placebo through injections every two weeks (starting with an initial loading dose). Throughout the study, you would complete questionnaires and have blood work done to measure how your immune system and airways respond. The study examines both how the medication affects you on a cellular level and whether it helps prevent asthma symptoms from worsening — though the exact duration and intensity of viral exposure (if any) would be explained during enrollment.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States